Overview

Status Migrainosus - Differentiating Between Responders and Non-responders

Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The main goal of this study is to determine whether it is possible - in the setup of routine clinical care - to identify in individual patients who are clear responders to drug X, common denominators that are absent in individual patients who are non-responders to the same drug, and vice versa. All currently available knowledge about migraine pathophysiology will be utilized, using as much time as is needed to ask as many questions as are necessary, in an attempt to profile clear responders and clear non-responders.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hartford HealthCare
Treatments:
BB 1101
Bupivacaine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Ketorolac
Ketorolac Tromethamine
Naratriptan